BeStock  
Stocks › Biotechnology › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2621Biotechnology
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership108.7%+1.21 pts vs. prior quarter
Institutions holding251-8 vs. prior quarter
Insider trades (recent)24 buys / 26 sellsNet selling
Short interest10.05% of floatDays to cover 8.3 · as of 30 Oct 2026
Short-sale volume share14.9%5-day average of daily volume

Short-sale volume as % of daily volume

7%12%17%22%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$18.94M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$16.9MSuper−$2.1MBig+$2.4MMid+$6.2MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 53.2% of shares outstanding.

Largest holders

  • Frazier Life Sciences Management, LP15.79%
  • Capital Research12.28%
  • FMR10.10%
  • RA Capital Management, L.P.7.96%
  • Forbion Capital Partners B.V.7.08%
  • Deerfield Management Company, L.P.3.56%
  • Viking Global Investors LP3.51%
  • Bain Capital Life Sciences Investors, LLC3.17%

By investor type

  • Mutual Fund46.40%
  • VC/PE Fund36.41%
  • Hedge Fund17.10%
  • Public Company3.39%
  • Family Office/Trust2.57%
  • Private Company1.98%
  • Individual/Insider0.88%
  • Sovereign Wealth Fund0.70%

Reported short interest has fallen from 10.59% to 10.05% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +1,777,081 10.1%
Capital Research Mutual Fund 2026/Q3 +769,602 12.3%
Barclays PLC Public Company 2026/Q3 +272,337 0.2%
Morgan Stanley Public Company 2026/Q3 +260,757 0.7%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +260,757 0.7%
American Century Investment Management Mutual Fund 2026/Q3 +180,590 0.7%
Mizuho Financial Group, Inc. Public Company 2026/Q3 +158,621 0.3%
Frazier Life Sciences Management, LP VC/PE Fund 2026/Q3 +850,000 15.8%
Orbis Investment Management Limited Mutual Fund 2026/Q3 +1,747,627 1.5%
FMR Mutual Fund 2026/Q3 +1,573,852 8.6%
Capital Research Mutual Fund 2026/Q3 +1,403,887 11.7%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +1,167,357 1.0%
Maverick Capital, Ltd. Hedge Fund 2026/Q3 +1,081,400 2.7%
Susquehanna International Group, LLP Private Company 2026/Q3 +736,502 0.6%
ODDO BHF Asset Management SAS Mutual Fund 2026/Q3 +619,793 0.5%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Sep 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -50,246 $25.03 74,636
13 Sep 2026 Michael Davidson Chief Executive Officer Open Market Acquisition +10,000 $22.65 915,285
3 Sep 2026 John Smither Independent Director Open Market Disposition -1,600 $25.32 720
31 Aug 2026 Robert Gunning Principal Accounting Officer, VP & Controller Other Acquisition +3,200 – 3,200
31 Aug 2026 Robert Gunning Principal Accounting Officer, VP & Controller Other Derivative Acquisition +14,000 $24.92 14,000
24 Aug 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Intent to Sell (Form 144) -250,000 – –
23 Aug 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -125,000 $26.91 74,636
19 Jul 2026 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -105,000 $31.71 2,353
21 Jun 2026 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -40,000 $30.73 2,353
25 May 2026 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -65,000 $35.69 2,353
10 Mar 2026 Louis Lange Independent Non-Executive Director Open Market Disposition -44,619 $31.23 2,320
8 Mar 2026 Louis Lange Independent Non-Executive Director Derivative Exercise and Retained +44,619 $11.50 46,939
8 Mar 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Derivative Exercise and Sale -300,000 $30.32 74,635
5 Mar 2026 Louis Lange Independent Non-Executive Director Open Market Disposition -28,186 $29.41 46,939
1 Mar 2026 Michael Davidson Chief Executive Officer Derivative Exercise and Sale -443,707 $33.25 296,506
1 Mar 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Intent to Sell (Form 144) -300,000 $31.18 –
25 Feb 2026 Michael Davidson Chief Executive Officer Derivative Exercise and Sale -306,293 $36.68 296,506
23 Feb 2026 Michael Davidson Chief Executive Officer Intent to Sell (Form 144) -750,000 $36.17 –
19 Feb 2026 Johannes Jacob Kastelein Founder, Chief Scientific Officer, Member of Executive Board & Director Open Market Disposition -45,481 $35.46 74,635
27 Jan 2026 Louise Kooij Former Chief Accounting Officer Derivative Exercise and Sale -72,428 $32.62 2,353

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 12,009,626 10.0% 8.3
15 Oct 2026 14,110,048 11.8% 10.6
30 Sep 2026 19,045,378 15.9% 9.4
15 Sep 2026 15,660,444 13.1% 9.9
31 Aug 2026 13,392,021 11.2% 13.4
14 Aug 2026 12,654,106 10.6% 9.9

Discussion

No comments yet — be the first to weigh in on NAMS.

Sign in to join the discussion.

Scroll to Top